About SeLux Diagnostics
SeLux Diagnostics is a company based in Cambridge (United States) founded in 2014. SeLux Diagnostics has raised $161.01 million across 11 funding rounds from investors including NIH, HHS and RA Capital. SeLux Diagnostics offers products and services including Selux NGP System, Selux Analyzer, and Selux Panels. SeLux Diagnostics operates in a competitive market with competitors including Cepheid, Day Zero Diagnostics, Specific Technologies, SpinDiag and InSilixa, among others.
- Headquarter Cambridge, United States
- SectorsHealthcare
- Website seluxdx.com
- Social LinkedIn X Instagram
- Legal Name Selux Diagnostics, Inc.
- Total Equity Funding$161.01M (USD)
in 11 rounds
- Latest Funding Round$48M (USD), Series C
Feb 2024
- InvestorsNIH
& 6 more
Products & Services of SeLux Diagnostics
SeLux Diagnostics offers a comprehensive portfolio of products and services, including Selux NGP System, Selux Analyzer, and Selux Panels.
Provides rapid antibiotic susceptibility testing for infectious diseases.
Offers precise cell health analysis for fast AST results.
Facilitates comprehensive menu for antimicrobial resistance testing.
Funding Insights of SeLux Diagnostics
SeLux Diagnostics has successfully raised a total of $161.01M across 11 strategic funding rounds. The most recent funding activity was a Series C round of $48 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $161.01M
- Total Rounds 11
- Last Round Series C — $48M
- First Round $216,546
(Apr 2016)
- Investors Count 7
Latest 10 of 11 funding rounds of SeLux Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | $48M | Series C | – | RA Capital Management | |
| Feb 2022 | $50M | Series C | – | RA Capital Management | |
| Oct 2021 | $2.8M | Grant | – | – | |
| Jun 2021 | $2.5M | Series B | – | – | – |
| Oct 2020 | $813,907 | Series B | – | – | – |
| Sep 2019 | $11.2M | Series B | – | – | – |
| Dec 2018 | $25M | Series B | – | Sands Capital Ventures | |
| Mar 2018 | $23.5M | Series B | – | – | – |
| Mar 2018 | $1.76M | Grant | – | – | |
| Jan 2018 | $3.09M | Grant | – | – |
7 investors in total: 7 institutional.
Investors in SeLux Diagnostics
SeLux Diagnostics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in life sciences & tech sectors | – | npv.vc | Cambridge, United States | |
Active, long-term growth equity investments are provided globally. | – | sandscapital.com | Arlington, United States | |
Private equity investments are directed across multiple sectors. | – | schoonercapital.com | Boston, United States | |
Growth stage tech & life sciences focused VC Firm investing in Asia and the US | – | sandscapitalventures.com | Arlington, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for SeLux Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SeLux Diagnostics
6 people are tracked at SeLux Diagnostics (6 in leadership).
| Name | Role | Group |
|---|---|---|
Adam Steel | Chief Implementation Officer | Leadership |
Steve Lufkin | CEO | Leadership |
Michele Healy | Chief Financial Officer | Leadership |
Jack Percoskie | CFO | Leadership |
Kassi Cox Whale, MBA | Director Of Marketing | Leadership |
Jingzi Sherman | VP, Medical and Scientific Affairs | Leadership |
Complete people profiles for SeLux Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SeLux Diagnostics
3 dated milestones of SeLux Diagnostics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded SeLux Diagnostics is founded.
- Funding First funding round of $217K.
- Funding Latest funding round, Series C, of $48.0M.
Competitors of SeLux Diagnostics
SeLux Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cepheid, Day Zero Diagnostics, Specific Technologies, SpinDiag and InSilixa, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cepheid.com | 1996 | Sunnyvale, United States | $19.1M | 1,299 | Developer of molecular diagnostic testing solutions | |
| dayzerodiagnostics.com | 2016 | Boston, United States | $48.6M | 48 | Genome sequencing diagnostics for infectious diseases are developed. | |
| specificdx.com | 2009 | San Francisco, United States | $30M | – | Detection and antibiotic susceptibility testing for blood infections are provided. | |
| spindiag.de | 2016 | – | $27.69M | – | Point-of-care systems for screening drug-resistant pathogens are developed. | |
| insilixa.com | 2012 | Sunnyvale, United States | $13M | 40 | Develops innovative point-of-care diagnostics using semiconductor-based CMOS biochip technology. | |
| microbedx.com | 2015 | Los Angeles, United States | $6.21M | – | Provider of the solutions for the detection of antibiotic susceptibility in urinary tract infections | |
| omixlabs.com | 2014 | Bengaluru, India | $138,095 | 1 | DNA testing platforms for pathogen diagnosis outside labs are developed. |
Detailed competitors of SeLux Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SeLux Diagnostics
The website of SeLux Diagnostics (seluxdx.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▼ 16.5% vs previous month
Latest news on Selux Diagnostics
Complete news archive for SeLux Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to SeLux Diagnostics
10 companies that operate in the same segment as SeLux Diagnostics (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about SeLux Diagnostics
SeLux Diagnostics was founded in 2014 and raised its 1st funding round 2 years after it was founded.
SeLux Diagnostics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
SeLux Diagnostics is a funded company, having raised a total of $161.01M across 11 funding rounds to date. The company's 1st funding round was a Grant of $3.09M, raised on Apr 2016.
Developer of alternatives to traditional ELISA assays. The company claims that its novel assay replaces the use of enzymes with an alternative that makes it more sensitive and faster than traditional ELISAs. Applications include point-of-care assays that have sensitivity similar to clinical laboratories.
SeLux Diagnostics's top competitors include Cepheid, Day Zero Diagnostics and Specific Technologies.
SeLux Diagnostics offers Selux NGP System, Selux Analyzer, and Selux Panels.
SeLux Diagnostics has 7 investors. Key investors include NIH, HHS, RA Capital, Northpond Ventures, and Sands Capital.
SeLux Diagnostics operates through Selux Diagnostics, Inc..